

Bilaga 8 Exkluderade studier

Kontinuerlig glukosmätning (CGM)

Systematiska översikter

Första författare, år och ref	Huvudorsak till exklusion
Floyd, 2012 [1]	Review
Leelarathna, 2011 [2]	Review
Meade, 2012 [3]	Review
Pickup, 2011 [4]	Review
Wojciechowski, 2011 [5]	Review

Originalstudier

Första författare, år och ref	Huvudorsak till exklusion
Ahmet, 2011 [6]	För kort studieperiod (3-dagarsstudie)
Allen, 2008 [7]	För kort uppföljningstid (8 veckor)
Anderson, 2011 [8]	Kontrollgruppen är inte tillräckligt beskriven
Beardsall, 2005 [9]	Ej relevant population (ej diabetes utan VLBW infants (very low and extremely low birthweight infants))
Beardsall, 2012 [10]	Ej relevant population (ej diabetes)
Beck, 2009 [11]	Ej relevant studiedesign (ingen kontrollgrupp)
Beck, 2009 [12]	Subanalys av Beck 2009 [11], inga separata barnresultat
Bode, 2008 [13]	Ej relevant intervention: jämför retrospektiv och real-time CGM
Buckingham, 2007 [14]	Ej relevant studiedesign (ingen kontrollgrupp)
Cemeroglu, 2010 [15]	Ej relevant studiedesign (ingen kontrollgrupp)
Chase, 2010 [16]	Ej relevant studiedesign (ingen kontrollgrupp)
Chase, 2001 [17]	För kort uppföljningstid (1 månad)
Chetty, 2008 [18]	Review
Cohen, 2009 [19]	Ej relevant studiedesign (ingen kontrollgrupp)
Conget, 2011 [20]	Pågående klinisk prövning
Davey, 2012 [21]	Ej relevant studiedesign (ingen kontrollgrupp)
De Block, 2008 [22]	Ej relevant population
de Bock, 2012 [23]	Review
Deiss, 2004 [24]	Ej relevant studiedesign (ingen kontrollgrupp, endast 6 veckors uppföljning)
Ehrhardt, 2011 [25]	Dubbelpublikation
Eugster, 2006 [26]	Review
Farrar, 2007 [27]	Ej originalstudie
Fiallo-Scharer, 2005 [28]	För kort studieperiod (3-dagarsstudie)
Fiallo-Scharer, 2011 [29]	Ej relevant studiedesign (ingen kontrollgrupp)
Fuld, 2010 [30]	Review
Group, 2010 [31]	Ej relevant studiedesign (ingen kontrollgrupp)
Group, 2010 [32]	Ej relevant studiedesign (ingen kontrollgrupp)
Halvorson, 2007 [33]	För kort studieperiod (1-månadsstudie)

Hughes, 2012 [34]	Ej relevant studiedesign (ingen kontrollgrupp)
Kaufman, 2001 [35]	Ej relevant studiedesign (ingen kontrollgrupp)
Kaufman, 2000 [36]	För kort studieperiod
Kordonouri, 2006 [37]	Ej relevant insulinsort
Leinung, 2010 [38]	Ej relevant studiedesign (ingen kontrollgrupp)
Liberatore, 2004 [39]	Ej relevant studiedesign (ingen kontrollgrupp)
Ludwig-Seibold, 2012 [40]	För kort uppföljningstid
Mack-Fogg, 2005 [41]	Barn under ett år
Madsen, 2011 [42]	Review
Maia, 2005 [43]	För kort studieperiod (72-timmarstudie)
Maia, 2007 [44]	För kort studieperiod (72-timmarstudie)
Messer, 2009 [45]	Ej relevant effektmått
O'Brien, 2009 [46]	Ej relevant studietyp
Pepper, 2012 [47]	Ingen kontrollgrupp, oklar population
Riveline, 2012 [48]	Ej relevant intervention
Ruedy, 2012 [49]	Review
Szypowska, 2012 [50]	Review
Tansey, 2011 [51]	Jämförande data för kontrollgrupp med SMBG saknas
Tansey, 2005 [52]	Ej relevant effektmått (kontrollerar mätsäkerheten vid CGM)
Tsalikian, 2012 [53]	Ej relevant studiedesign (ingen kontrollgrupp)
Weinzimer, 2008 [54]	Ej relevant studiedesign (ingen kontrollgrupp)
Wolfsdorf, 2009 [55]	Ingen studie (kommentar)
Yogev, 2003 [56]	Ej relevant studietyp

Sensor-augmented pump (SAP)

Systematiska översikter

Första författare, år och ref	Huvudorsak till exklusion
Golden, 2012 [57]	Ej relevant intervention

SAP originalstudier

Första författare, år och ref	Huvudorsak för exklusion
Battelino, 2012 [58]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning"
Bergental, 2011 [59]	Ej relevant studiedesign (ingen kontrollgrupp)
Danne, 2011 [60]	För kort uppföljningstid (6 veckor)
Frontino, 2012 [61]	Ej relevant studiedesign (ingen kontrollgrupp)
Garg, 2012 [62]	Ej relevant intervention och effektmått (värderar stoppfunktion i pumpen)
Garg, 2006 [63]	Ej relevant intervention och effektmått (värderar stoppfunktion i pumpen) samt för kort studieperiod (1 dagars studie)
Hirsch, 2008 [64]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning"
Hovorka, 2011 [65]	Ej relevant intervention (closed-loop)
Kamble, 2012 [66]	Ej relevant effektmått (jämför tidsåtgången för diabetesvård)
Kordonouri, 2012 [67]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning"

Kordonouri, 2010 [68]	Redovisas endast i SBU:s rapport "Kontinuerlig subkutan glukosmätning"
Lee, 2007 [69]	Uppgifter om insulin sorter saknas
Petrovski, 2011 [70]	Ej relevant intervention
Radermecker, 2010 [71]	Ej relevant studiedesign (ingen kontrollgrupp, före- efter-studie)
Scaramuzza, 2011 [72]	Ej relevant studiedesign
Schmidt, 2012 [73]	Ej relevant studiedesign (follow-up efter studie, ingen kontrollgrupp)
Warner, 2011 [74]	Endast abstrakt
Yeaw, 2012 [75]	Review
Zucchini, 2011 [76]	För kort studieperiod (3-dagars studie)

Hälsoekonomiska studier (CGM och SAP)

Första författare, år och ref	Huvudsaklig exklusionsorsak
OHTA, 2011[77]	Ej relevant, analyserar endast interventionskostnaden
Aubry, 2005[78]	Ej relevant, inget om hälsoekonomiska utfall
Bartelme, 2009[79]	Ej relevant, diskussionsartikel
Graham, 2010[80]	Endast abstrakt
Hanas, 2011[81]	Endast abstrakt
Huang, 2010[82]	Errata tillhörande annan artikel
Kamble, 2011a[83]	Endast abstrakt
Kamble, 2011b[84]	Endast abstrakt
Kamble, 2012[85]	Ej relevant, analyserar endast patientkostnader
Lynch, 2010[86]	Ej relevant, fel studiedesign
Lynch, 2012[87]	Endast abstrakt
Roze ,2012b[88]	Endast abstrakt
Roze, 2012a[89]	Endast abstrakt
Skyler, 2000[90]	Ej relevant, ej jämförande studiedesign
Van Genug, 2010[91]	Endast abstrakt

Referenslista

1. Floyd B, Chandra P, Hall S, Phillips C, Alema-Mensah E, Strayhorn G, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. *J Diabetes Sci Technol* 2012;6:1094-102.
2. Leelarathna L, Guzder R, Muralidhara K, Evans ML. Diabetes: glycaemic control in type 1. *Clin Evid (Online)* 2011;2011:
3. Meade LT. The use of continuous glucose monitoring in patients with type 2 diabetes. *Diabetes Technol Ther* 2012;14:190-5.
4. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ* 2011;343:d3805.
5. Wojciechowski P, Rys P, Lipowska A, Gaweska M, Malecki MT. Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes: systematic review and meta-analysis. *Pol Arch Med Wewn* 2011;121:333-43.

6. Ahmet A, Dagenais S, Barrowman NJ, Collins CJ, Lawson ML. Prevalence of nocturnal hypoglycemia in pediatric type 1 diabetes: a pilot study using continuous glucose monitoring. *J Pediatr* 2011;159:297-302 e1.
7. Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. *Diabetes Res Clin Pract* 2008;80:371-9.
8. Anderson J, Attvall S, Sternemalm L, Pivodic A, Fahlen M, Hanas R, et al. Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice. *J Diabetes Sci Technol* 2011;5:1472-9.
9. Beardsall K, Ogilvy-Stuart AL, Ahluwalia J, Thompson M, Dunger DB. The continuous glucose monitoring sensor in neonatal intensive care. *Arch Dis Child Fetal Neonatal Ed* 2005;90:F307-10.
10. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Vanweissenbruch M, Midgley P, et al. Validation of the continuous glucose monitoring sensor in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2012;
11. Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. *Diabetes Care* 2009;32:1947-53.
12. Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. *Diabetes Care* 2009;32:1378-83.
13. Bode B, Silver M, Weiss R, Martin K. Evaluation of a continuous glucose monitoring system for home-use conditions. *Manag Care* 2008;17:40-5.
14. Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, et al. Continuous glucose monitoring in children with type 1 diabetes. *J Pediatr* 2007;151:388-93, 93 e1-2.
15. Cemeroglu AP, Stone R, Kleis L, Racine MS, Postellon DC, Wood MA. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients' and caregivers' perception of benefit. *Pediatr Diabetes* 2010;11:182-7.
16. Chase HP, Beck RW, Xing D, Tamborlane WV, Coffey J, Fox LA, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. *Diabetes Technol Ther* 2010;12:507-15.
17. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. *Pediatrics* 2001;107:222-6.
18. Chetty VT, Almulla A, Oduyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HbA1c) levels in Type I diabetic patients: a systematic review. *Diabetes Res Clin Pract* 2008;81:79-87.
19. Cohen O, Korner A, Chlup R, Zoupas CS, Ragozin AK, Wudi K, et al. Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry. *J Diabetes Sci Technol* 2009;3:804-11.
20. Conget I, Battelino T, Gimenez M, Gough H, Castaneda J, Bolinder J. The SWITCH study (sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy. *Diabetes Technol Ther* 2011;13:49-54.
21. Davey RJ, Stevens K, Jones TW, Fournier PA. The effect of short-term use of the Guardian RT continuous glucose monitoring system on fear of hypoglycaemia in patients with type 1 diabetes mellitus. *Prim Care Diabetes* 2012;6:35-9.
22. De Block C, Manuel-y-Keenoy B, Van Gaal L. A review of current evidence with continuous glucose monitoring in patients with diabetes. *J Diabetes Sci Technol* 2008;2:718-27.

23. de Bock M, Gunn AJ, Holt JA, Derraik JG, Reed P, Cutfield W, et al. Impact of insulin pumps on glycaemic control in a pump-naive paediatric regional population. *J Paediatr Child Health* 2012;48:247-52.
24. Deiss D, Hartmann R, Hoeffe J, Kordonouri O. Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy. *Pediatr Diabetes* 2004;5:117-21.
25. Ehrhardt NM, Chellappa M, Walker MS, Fonda SJ, Vigersky RA. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. *J Diabetes Sci Technol* 2011;5:668-75.
26. Eugster EA, Francis G. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes. *Pediatrics* 2006;118:e1244-9.
27. Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. *Cochrane Database Syst Rev* 2007;CD005542.
28. Fiallo-Scharer R. Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. *J Clin Endocrinol Metab* 2005;90:3387-91.
29. Fiallo-Scharer R, Cheng J, Beck RW, Buckingham BA, Chase HP, Kollman C, et al. Factors predictive of severe hypoglycemia in type 1 diabetes: analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. *Diabetes Care* 2011;34:586-90.
30. Fuld K, Conrad B, Buckingham B, Wilson DM. Insulin pumps in young children. *Diabetes Technol Ther* 2010;12 Suppl 1:S67-71.
31. Group CGMS. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. *Diabetes Care* 2010;33:1004-8.
32. Group CGMS. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. *Diabetes Care* 2010;33:17-22.
33. Halvorson M, Carpenter S, Kaiserman K, Kaufman FR. A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump. *J Pediatr* 2007;150:103-05 e1.
34. Hughes CR, McDowell N, Cody D, Costigan C. Sustained benefits of continuous subcutaneous insulin infusion. *Arch Dis Child* 2012;97:245-7.
35. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care* 2001;24:2030-4.
36. Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. *Diabetes Care* 2000;23:579-82.
37. Kordonouri O, Hartmann R, Lauterborn R, Barnekow C, Hoeffe J, Deiss D. Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients: one-year follow-up comparison by matched-pair analysis. *Diabetes Care* 2006;29:133-34.
38. Leinung M, Thompson S, Nardacci E. Benefits of continuous glucose monitor use in clinical practice. *Endocr Pract* 2010;16:371-5.
39. Liberatore R, Jr., Perlman K, Buccino J, Artiles-Sisk A, Daneman D. Continuous subcutaneous insulin infusion pump treatment in children with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab* 2004;17:223-6.
40. Ludwig-Seibold CU, Holder M, Rami B, Raile K, Heidtmann B, Holl RW. Continuous glucose monitoring in children, adolescents, and adults with type 1 diabetes mellitus: analysis from the prospective DPV diabetes documentation and quality management system from Germany and Austria. *Pediatr Diabetes* 2012;13:12-4.

41. Mack-Fogg JE, Orlowski CC, Jospe N. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. *Pediatr Diabetes* 2005;6:17-21.
42. Madsen AB, Secher AL, Damm P, Mathiesen ER. [Continuous glucose monitoring in pregnancies complicated by diabetes]. *Ugeskr Laeger* 2011;173:1640-5.
43. Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system to detect unrecognized hypoglycemia in children and adolescents with type 1 diabetes. *Arq Bras Endocrinol Metabol* 2005;49:569-74.
44. Maia FFR, Araújo LR. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. *Diabetes Research & Clinical Practice* 2007;75:30-34.
45. Messer L, Ruedy K, Xing D, Coffey J, Englert K, Caswell K, Ives B. Educating families on real time continuous glucose monitoring: the DirecNet navigator pilot study experience. *Diabetes Educ* 2009;35:124-35.
46. O'Brien B. Continuous glucose monitoring improved glycaemic control in pregnant women with diabetes and reduced infant macrosomia. *Evidence Based Nursing* 2009;12:43-43.
47. Pepper GM, Steinsapir J, Reynolds K. Effect of short-term iPRO continuous glucose monitoring on hemoglobin A1c levels in clinical practice. *Diabetes Technol Ther* 2012;14:654-7.
48. Riveline JP, Schaepelynck P, Chaillous L, Renard E, Sola-Gazagnes A, Penfornis A, et al. Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. *Diabetes Care* 2012;35:965-71.
49. Ruedy KJ, Tamborlane WV. The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence. *J Cardiovasc Transl Res* 2012;5:380-7.
50. Szybowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. *Eur J Endocrinol* 2012;166:567-74.
51. Tansey M, Laffel L, Cheng J, Beck R, Coffey J, Huang E, et al. Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes. *Diabet Med* 2011;28:1118-22.
52. Tansey MJ, Beck RW, Buckingham BA, Mauras N, Fiallo-Scharer R, Xing D, et al. Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. *Diabetes Technol Ther* 2005;7:109-14.
53. Tsalikian E, Fox L, Weinzimer S, Buckingham B, White NH, Beck R, et al. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. *Pediatr Diabetes* 2012;13:301-7.
54. Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, et al. FreeStyle navigator continuous glucose monitoring system use in children with type 1 diabetes using glargine-based multiple daily dose regimens: results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group. *Diabetes Care* 2008;31:525-7.
55. Wolfsdorf JI. How effective is continuous glucose monitoring in intensively treated type 1 diabetes mellitus? *Nat Clin Pract Endocrinol Metab* 2009;5:134-5.
56. Yogev Y, Chen R, Ben-Haroush A, Phillip M, Jovanovic L, Hod M. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. *Obstet Gynecol* 2003;101:633-8.
57. Golden SH, Brown T, Yeh HC, Maruthur N, Ranasinghe P, Berger Z, et al. 2012;
58. Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. *Diabetologia* 2012;55:3155-62.

59. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. *Diabetes Care* 2011;34:2403-5.
60. Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. *Diabetes Technol Ther* 2011;13:1129-34.
61. Frontino G, Bonfanti R, Scaramuzza A, Rabbone I, Meschi F, Rigamonti A, et al. Sensor-augmented pump therapy in very young children with type 1 diabetes: an efficacy and feasibility observational study. *Diabetes Technol Ther* 2012;14:762-4.
62. Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. *Diabetes Technol Ther* 2012;14:205-9.
63. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. *Diabetes Care* 2006;29:2644-49.
64. Hirsch IB, Abelson J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. *Diabetes Technol Ther* 2008;10:377-83.
65. Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. *BMJ* 2011;342:d1855.
66. Kamble S, Weinfurt KP, Schulman KA, Reed SD. Patient Time Costs Associated with Sensor-Augmented Insulin Pump Therapy for Type 1 Diabetes: Results from the STAR 3 Randomized Trial. *Med Decis Making* 2012;
67. Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, et al. Sensor augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric Onset Study. *Pediatr Diabetes* 2012;13:515-8.
68. Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. *Diabetologia* 2010;53:2487-95.
69. Lee SW, Sweeney T, Clausen D, Kolbach C, Hassen A, Firek A, et al. Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump naive patients with type 1 diabetes; single center pilot study experience. *J Diabetes Sci Technol* 2007;1:400-4.
70. Petrovski G, Dimitrovski C, Bogoev M, Milenkovic T, Ahmeti I, Bitovska I. Is there a difference in pregnancy and glycemic outcome in patients with type 1 diabetes on insulin pump with constant or intermittent glucose monitoring? A pilot study. *Diabetes Technol Ther* 2011;13:1109-13.
71. Radermecker RP, Saint Remy A, Scheen AJ, Bringer J, Renard E. Continuous glucose monitoring reduces both hypoglycaemia and HbA1c in hypoglycaemia-prone type 1 diabetic patients treated with a portable pump. *Diabetes Metab* 2010;36:409-13.
72. Scaramuzza AE, Iafusco D, Rabbone I, Bonfanti R, Lombardo F, Schiaffini R, et al. Use of integrated real-time continuous glucose monitoring/insulin pump system in children and adolescents with type 1 diabetes: a 3-year follow-up study. *Diabetes Technol Ther* 2011;13:99-103.
73. Schmidt S, Norgaard K. Sensor-Augmented Pump Therapy at 36 Months. *Diabetes Technol Ther* 2012;
74. Warner D, Speer H, McDaniels A, Less J, Daniels M. Use of Carelink Pro Diabetes Therapy Management Software for Improving Patient Outcomes Using Sensor Augmented Pump (SAP) Therapy. *Journal of Pediatric Nursing* 2011;26:282-82.
75. Yeaw J, Lee WC, Aagren M, Christensen T. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. *J Manag Care Pharm* 2012;18:21-32.

76. Zucchini S, Scipione M, Balsamo C, Maltoni G, Rollo A, Molinari E, et al. Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children. *Diabetes Technol Ther* 2011;13:1187-93.
77. Continuous glucose monitoring for patients with diabetes: an evidence-based analysis. *Ont Health Technol Assess Ser* 2011;11:1-29.
78. Aubry W. Reimbursement and coverage implications for CGM. *Diabetes Technol Ther* 2005;7:797-800.
79. Bartelme A, Bridger P. The role of reimbursement in the adoption of continuous glucose monitors. *J Diabetes Sci Technol* 2009;3:992-5.
80. Graham C, Agardh DC, Gerhardsson P, Hankin CS. Comparison of total annual direct costs among Swedish residents with poorly controlled type 1 diabetes: Standard care versus real-time continuous glucose monitoring. *Diabetologia* 2010;53:S26.
81. Hanas R, Argadh CD, Graham C, Gerhardsson P, Hankin CS. Clinical and economic outcomes of continuous glucose monitoring among Swedish residents with poorly controlled type 1 diabetes. *Diabetes Technology and Therapeutics* 2011;13:230.
82. Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes (*Diabetes Care* (2010) 33, (1269-1274)). *Diabetes Care* 2010;33:2129.
83. Kamble S, Perry BM, Shafiroff J, Schulman KA, Reed SD. The cost-effectiveness of initiating sensor-augmented pump therapy versus multiple daily injections of insulin in adults with type 1 diabetes: Evaluating a technology in evolution. *Value in Health* 2011;14:A82.
84. Kamble S, Weinfurt KP, Perry BM, Schulman KA, Reed SD. Patient time and indirect costs associated with sensor-augmented insulin pump therapy in type 1 diabetes. *Value in Health* 2011;14:A84.
85. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. *Value Health* 2012;15:632-8.
86. Lynch PM, Riedel AA, Samant N, Fan Y, Peoples T, Levinson J, Lee SW. Resource utilization with insulin pump therapy for type 2 diabetes mellitus. *Am J Manag Care* 2010;16:892-6.
87. Lynch P, Attvall S, Persson S, Barsoe C, Gerdtham U. Routine use of personal continuous glucose monitoring system with insulin pump in Sweden. *Diabetologia* 2012;55:S432.
88. Roze S, Valentine WJ, Hanas R, Barsoe C. Projection of health economics benefits of continuous glucose monitoring versus self monitoring of blood glucose in type 1 diabetes, in Sweden. *Value in Health* 2012;15:A69.
89. Roze S, Lynch P, Cook M. Projection of long term health-economic benefits of Continuous Glucose Monitoring (CGM) versus self monitoring of blood glucose in type 1 diabetes, a UK perspective. *Diabetologia* 2012;55:S427.
90. Skyler JS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. *Diabetes Technol Ther* 2000;2 Suppl 1:S7-12.
91. Van Genugten ML. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes patients in the Netherlands. *Value in Health* 2010;13:A292.